## Prognostic Factors in Advanced Ovarian Cancer **Key Point:** Optimal cytoreduction to residual disease <1 cm (ideally <0.1 cm) remains the single most powerful independent prognostic factor for overall survival in advanced ovarian cancer, regardless of whether surgery is primary or interval. ### Evidence Base: - **Landmark studies** (GOG 182, EORTC 55971) demonstrate that residual disease status is the strongest modifiable prognostic factor - Patients with residual disease <1 cm have significantly superior OS compared to those with >1 cm residual disease - This holds true even in the neoadjuvant setting (EORTC 55971: median OS 29 months for <1 cm vs. 18 months for >1 cm) ### Why Optimal Cytoreduction Matters: - **Chemotherapy penetration:** Smaller residual tumors have better drug penetration and oxygenation - **Tumor biology:** Ability to achieve optimal cytoreduction reflects tumor aggressiveness and chemosensitivity - **Modifiable factor:** Unlike stage or histology, cytoreduction is a surgical outcome that directly impacts treatment efficacy ### Clinical Pearl: In this case, despite residual disease of 1.2 cm (suboptimal), the patient still received systemic therapy. However, the prognostic hierarchy remains: optimal cytoreduction (R0/R1) > platinum sensitivity > chemotherapy completion. **High-Yield:** For NEET PG: "Residual disease <1 cm" is the answer to ~90% of "best prognostic factor" questions in ovarian cancer.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.